Compare DHIL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 391.1M |
| IPO Year | 1996 | 1996 |
| Metric | DHIL | LCTX |
|---|---|---|
| Price | $174.96 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 13.8K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 14.37 | N/A |
| EPS | ★ 17.91 | N/A |
| Revenue | ★ $145,201,729.00 | $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | 6.69 | ★ 53.24 |
| 52 Week Low | $114.11 | $0.40 |
| 52 Week High | $173.70 | $2.09 |
| Indicator | DHIL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 56.12 |
| Support Level | $171.71 | $1.66 |
| Resistance Level | N/A | $1.84 |
| Average True Range (ATR) | 0.65 | 0.08 |
| MACD | 0.16 | 0.03 |
| Stochastic Oscillator | 98.87 | 71.67 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.